Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

EHU140941

Sigma-Aldrich

MISSION® esiRNA

targeting human BMF

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

UNSPSC Code:
41105324
NACRES:
NA.51

description

Powered by Eupheria Biotech

Quality Level

100

product line

MISSION®

form

lyophilized powder

esiRNA cDNA target sequence

GAGGTACAGATTGCCCGAAAGCTTCAGTGCATTGCAGACCAGTTCCACCGGCTTCATGTGCAGCAACACCAGCAGAACCAAAATCGTGTGTGGTGGCAGATCCTCCTCTTCCTGCACAACCTTGCTTTGAATGGAGAAGAGAACAGGAACGGGGCAGGCCCTAGGTGAGGGTGGGCTGCCCTCTTCACATGGGGCACCAGGAACACCGTCTGGAACAGGAAGGACATCGGGCAGGACTGACACTGTGTCTTGTGAAATTGTTTTTTTGTTGTTATTTTGTGTTTTAATTTTTTTTAATTTCTCTCTGAGTGTACATACAACATACTCAAGCGGGACCTTCTTTCTCTGTCAGGCCCTTGACCTGGAATGGGGGCCTTTGTCAAACACTGTTGAAGGAGAGGCTGATGTGTCTGTGATGGTGAGAATTCCCA

Ensembl | human accession no.

ENSG00000104081

NCBI accession no.

NM_001003940

shipped in

ambient

storage temp.

−20°C

Gene Information

human ... BMF(90427) , BMF(90427)

General description

MISSION esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

Legal Information

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class

10 - Combustible liquids

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
QCS
KUT
KIT

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Y Kang et al.
Cell death & disease, 5, e1476-e1476 (2014-10-17)
Histone deacetylase (HDAC) inhibitors are undergoing clinical trials as anticancer agents, but some exhibit resistance mechanisms linked to anti-apoptotic Bcl-2 functions, such as BH3-only protein silencing. HDAC inhibitors that reactivate BH3-only family members might offer an improved therapeutic approach. We
Kari J Kurppa et al.
Cancer cell, 37(1), 104-122 (2020-01-15)
Eradicating tumor dormancy that develops following epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment of EGFR-mutant non-small cell lung cancer, is an attractive therapeutic strategy but the mechanisms governing this process are poorly understood. Blockade of ERK1/2 reactivation

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service